Sildenafil is called Ravatio for pulmonary arterial hypertension and Viagra for erectile dysfunction

In a antecedence reappraisal the US Food and Drug Term of office (FDA) has approved Revatio (™) (sildenafil) as a aid for pulmonary arterial hypertension (PAH).
The FDA subject matter was based on the preceding experimental and clinical investigations, which were initiated and largely performed at the Establishment of Giessen Lung Center field (UGLC) and led to a worldwide multicenter field of study.

Pulmonary Hypertension (PH) is chronic and life-shortening vascular disease characterized by high pressing in the lung ancestry vessels lead to right field affection happening.
In a translational investigating drive realizing the "bench to bedside" attack, a team of physicians led by Prof.
Friedrich Grimminger and Dr.
Ardeschir Ghofrani organized the "Giessen Everest Experiment" with the aim to further investigate the therapeutic electrical phenomenon of sildenafil (Viagra™) in humans: The changes observed in healthy mountaineers simulate disease processes in patients excruciation from chronic lung diseases.
This high ALT examination clearly documented the selective pulmonary vasodilatory impression of sildenafil.
The capital reduces pulmonary hypertension, improves gas commercialism and increases exercising tolerance.
Further clinical studies in Giessen in patients wretchedness from different forms of PH (adults, children and infants) have confirmed these results and lead to an international multicenter thoughtfulness.
The results of this large randomized, double-blind, placebo-controlled room were offset presented by Giessen scientists at the Existence Association of the American Body of Pectus Physicians in September 2004.
This is a part of article Sildenafil is called Ravatio for pulmonary arterial hypertension and Viagra for erectile dysfunction Taken from "Soft Tab Viagra" Information Blog